Mark Steven Ross Michaels

US Patent:

20130129725, May 23, 2013

Filed:

Apr 13, 2011

Appl. No.:

13/641041

Inventors:

Ian Foltz - Burnaby, CA
Seog Joon Han - Simi Valley CA, US
Susie Miki Harris - Newbury Park CA, US
Chadwick Terence King - North Vancouver, CA
Yang Li - Mountain View CA, US
Ji Lu - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - San Diego CA, US

International Classification:

A61K 39/395
C07K 16/40

US Classification:

4241341, 5303891, 5303873, 53038826, 4241581, 536 2353, 4353201, 435338, 435 696, 530328, 530327

Abstract:

The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

US Patent:

20130225484, Aug 29, 2013

Filed:

Feb 25, 2013

Appl. No.:

13/775756

Inventors:

Mark Leo Michaels - Encino CA, US
Thomas C. Boone - Newbury Park CA, US
Rohini Deshpande - Camarillo CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Huiquan Han - Thousand Oaks CA, US

Assignee:

AMGEN - Thousand Oaks CA

International Classification:

C07K 14/71

US Classification:

514 48, 530350, 5303873, 536 235, 4353201, 435325, 435 691, 514 212, 514 154, 514 166, 514 69, 514 167

Abstract:

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

US Patent:

60968656, Aug 1, 2000

Filed:

May 6, 1996

Appl. No.:

8/643704

Inventors:

Mark Michaels - Encino CA

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 14435
C12N 1511
C12N 510

US Classification:

530350

Abstract:

The present invention relates to mutants of the green fluorescent protein having improved fluorescent properties at 37. degree. C. The mutants provide for improved methods of monitoring gene expression, e. g. , for use as cell markers or protein expression indicators in prokaryotic and, especially, eucaryotic systems where the standard physiological temperature is 37. degree. C.

US Patent:

20220195022, Jun 23, 2022

Filed:

Dec 21, 2021

Appl. No.:

17/558032

Inventors:

- Thousand Oaks CA, US
Irwin CHEN - Los Angeles CA, US
Su CHONG - Oxnard CA, US
Bryna FUCHSLOCHER - Thousand Oaks CA, US
Kevin GRAHAM - Thousand Oaks CA, US
Agnes Eva HAMBURGER - Newbury Park CA, US
Mark Leo MICHAELS - Encino CA, US
Christopher MOHR - Newbury Park CA, US
Derek E. PIPER - Santa Clara CA, US
Kenneth William WALKER - Newbury Park CA, US
Zhulun WANG - Los Altos CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/18
C07K 16/28
A61P 25/06
A61K 38/22

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

US Patent:

20210017261, Jan 21, 2021

Filed:

Jul 1, 2020

Appl. No.:

16/919032

Inventors:

- Thousand Oaks CA, US
Irwin CHEN - Los Angeles CA, US
Su CHONG - Oxnard CA, US
Bryna FUCHSLOCHER - Thousand Oaks CA, US
Kevin GRAHAM - Thousand Oaks CA, US
Agnes Eva HAMBURGER - Newbury Park CA, US
Mark Leo MICHAELS - Encino CA, US
Christopher MOHR - Newbury Park CA, US
Derek E. PIPER - Santa Clara CA, US
Kenneth William WALKER - Newbury Park CA, US
Zhulun WANG - Palo Alto CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/18
C07K 16/28
A61P 25/06
A61K 38/22

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

US Patent:

20200283504, Sep 10, 2020

Filed:

Apr 18, 2019

Appl. No.:

16/388561

Inventors:

- Thousand Oaks CA, US
Mark Leo MICHAELS - Encino CA, US
Thomas Charles BOONE - Newbury Park CA, US
Rohini DESHPANDE - Camarillo CA, US
Yue-Sheng LI - Cambridge MA, US
Huiquan HAN - Thousand Oaks CA, US

International Classification:

C07K 14/71
C07K 14/495

Abstract:

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

US Patent:

20190218279, Jul 18, 2019

Filed:

Jan 11, 2019

Appl. No.:

16/246326

Inventors:

- Thousand Oaks CA, US
Irwin CHEN - Los Angeles CA, US
Su CHONG - Oxnard CA, US
Bryna FUCHSLOCHER - Thousand Oaks CA, US
Kevin GRAHAM - Thousand Oaks CA, US
Agnes Eva HAMBURGER - Newbury Park CA, US
Mark Leo MICHAELS - Encino CA, US
Christopher MOHR - Newbury Park CA, US
Derek E. PIPER - Santa Clara CA, US
Kenneth William WALKER - Newbury Park CA, US
Zhulun WANG - Palo Alto CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/18
A61P 25/06
A61K 38/22

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

US Patent:

20170183391, Jun 29, 2017

Filed:

Jan 22, 2016

Appl. No.:

15/004375

Inventors:

- Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Thomas Charles Boone - Newbury Park CA, US
Rohini Deshpande - Camarillo CA, US
Yue-Sheng Li - Cambridge MA, US
Huiquan Han - Thousand Oaks CA, US

International Classification:

C07K 14/71

Abstract:

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.